Preventing Shingles and Its Complications in Older Persons
NEJM 375:1079-1080, Neuzil, K.M.,et al, 2016
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
NEJM 376:221-234,280, Hauser, S.L.,et al, 2017
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017
Safety and Diagnostic Value of Brain Biopsy in HIV patients: a Case Series and Meta-Analysis of 1209 Patients
JNNP 87:722-733, Lee, A.M.,et al, 2016
Influenza Vaccination and Cardiovascular Risk in Patients with Recent TIA and Stroke
Neurol 82:1905-1913, Lavallee, P.C.,et al, 2014
Evidence-based Guideline: Antiepileptic Drug Selection for People with HIV/AIDS
Neurol 78:139-145, Birbeck,G.L.,et al, 2012
Neurologic Outcomes and Adjunctive Steroids in HIV Patients with Severe Cerebral Toxoplasmosis
Neurol 79:1762-1766, Sonneville, R.,et al, 2012
Effect of Vaccines on Bacterial Meningitis Worldwide
Lancet 380:1703-1711,1623, McIntyre, P.,et al, 2012
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Mechanisms of Fingolimods Efficacy and Adverse Effects in Multiple Sclerosis
Ann Neurol 69:759-777, Cohen, J.A. & Chun, J., 2011
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
Acyclovir Resistance in Herpes Simplex Encephalitis
Ann Neurol 67:830-833, Schulte,E.C., et al, 2010
DNA �-Amyloid1-42 Trimer Immunization for Alzheimer Disease in a Wild-Type Mouse Model
JAMA 302:1796-1802, Lambracht-Washington,D.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Controlled Trial of High-Concentration Capsaicin Patch for Treatment of Painful HIV Neuropathy
Neurol 70:2305-2313, Simpson,D.M.,et al, 2008
Long-Term Effects of A�42 Immunisation in Alzheimers Disease: Follow-Up of a Randomised, Placebo-Controlled Phase I Trial
Lancet 372:216-223,180, Holmes,C.,et al., 2008
Assessment: The Use of Natalizumab (Tysabri) for the Treatment of Multiple Sclerosis (An Evidence-Based Review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 71:766-773, Goodin,D.S.,et al., 2008